Craig S Chertack, MD | |
225 Memorial Dr, Berlin, WI 54923-1243 | |
(920) 361-1313 | |
Not Available |
Full Name | Craig S Chertack |
---|---|
Gender | Male |
Speciality | Specialist |
Location | 225 Memorial Dr, Berlin, Wisconsin |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811979487 | NPI | - | NPPES |
076011 | Other | NY | MEDICARE GROUP NUMBER |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | 169890 (New York) | Secondary |
207X00000X | Orthopaedic Surgery | 18247 (Wisconsin) | Secondary |
174400000X | Specialist | 169890 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Craig S Chertack, MD 331 Forestview Dr, Williamsville, NY 14221-1460 Ph: (716) 689-7541 | Craig S Chertack, MD 225 Memorial Dr, Berlin, WI 54923-1243 Ph: (920) 361-1313 |
News Archive
"As Washington prepares to host the International AIDS Conference from July 22-27, PBS NewsHour will profile some of the parallel stories unfolding around the epidemic on opposite ends of the globe," the news service writes. In the first of these stories, the news service profiles two individuals - John Johnson in Washington, D.C., and Alice Sibanda in Hwange, Zimbabwe - who as children lost their parents to the HIV/AIDS epidemic.
HHS Secretary Mike Leavitt has announced the awarding of $56.9 million by the National Institutes of Health's (NIH) National Center on Minority Health and Health Disparities (NCMHD).
According to Australian researchers exercise appears to slow down the growth of cancer cells because it increases a protein that blocks cell growth and induces cell death.
Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.
› Verified 4 days ago